Ann: Medgate commences European ResAppDx trial, page-19

Agree, the high end of upside is;
200 doctors * 20 calls a day * 50% respiratory case * 30%- 75% use Resapp (This could be wrong) * $5 a use = ~1250 uses a day = $6,250 a day or ~$2.2m annualized. I get these are high level and could move +/- reasonable % either way.

$2.2m is not even half a year of runway for company.

Still if we get anything near that upside it would trigger a massive rerate of shares.

I expect a CR once the Share price rises on any further positive news.